WilmerHale Reps Spring Bank Pharmaceuticals in IPO

WilmerHale Reps Spring Bank Pharmaceuticals in IPO

Firm News

WilmerHale represented Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, in its initial public offering.
 
The WilmerHale team on the transaction was led by Partner Stuart Falber and included Counsel Carolyn Rucci, Senior Associate Mia Kelley, and Associates Alyce Chen and Leah Segal.
 
For more information read Spring Bank's press release.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.